Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2026-03-06 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is a formal notification of share awards granted to Persons Discharging Managerial Responsibilities (PDMRs), specifically the CEO and CFO of AstraZeneca. It follows the standard regulatory format for reporting insider transactions and share-based compensation under the EU Market Abuse Regulation. While it mentions remuneration plans, it is primarily a disclosure of specific transactions by directors/executives, which falls under the 'Director's Dealing' category.
2026-03-06 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a regulatory announcement from AstraZeneca PLC regarding 'Voting rights and capital' in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. It provides the total number of voting rights and issued share capital. While it relates to capital, it is a standard regulatory disclosure required by the FCA, which fits best under the 'Regulatory Filings' (RNS) category as it is a routine notification of share capital and voting rights rather than a specific share issuance or repurchase event.
2026-03-02 English
AstraZeneca prices a $2bn bond offering
Capital/Financing Update
2026-02-26 English
AstraZeneca prices a $2bn bond offering
Capital/Financing Update Classification · 1% confidence The document is a news release announcing a $2 billion bond offering by AstraZeneca. It details the tranches, coupon rates, maturity dates, and the intended use of proceeds. This falls squarely under the definition of a capital/financing update, as it describes the company's fundraising activity and changes to its capital structure through debt issuance.
2026-02-26 English
Filing of Form 20-F with SEC
Report Publication Announcement Classification · 1% confidence The document is a short announcement (2859 characters) from AstraZeneca PLC notifying the market that it has filed its 2025 Annual Report on Form 20-F with the SEC. It provides links to where the report can be accessed rather than containing the report itself. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2026-02-25 English
20-F - ASTRAZENECA PLC (0000901832) (Filer)
Annual Report FY 2025
2026-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.